Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

UK Government Supports Moves For Pharma Companies To Communicate Directly With Patients
The UK government would like to allow pharmaceutical companies to provide patients with more information about prescription drugs, according to an article published in Pulse. UK ministers view the European Commission"s proposals positively - these proposals would greatly extend the communication permitted between companies and patients. Currently, European Law limits such communication to patient safety leaflets.

Triglycerides Implicated In Diabetes Nerve Loss
A common blood test for triglycerides - a well-known cardiovascular disease risk factor - may also for the first time allow doctors to predict which patients with diabetes are more likely to develop the serious, common complication of neuropathy.
News of the day
New Data From Satraplatin Phase 3 Trial In Second-Line Castrate-Refractory Prostate Cancer Presented At 2009 ASCO Annual Meeting
GPC Biotech AG (FRANKFURT: GPC) (XETRA: GPC) announced that data from the double- blind, randomized satraplatin Phase 3 trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer), were presented at the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The SPARC trial evaluated satraplatin plus prednisone versus placebo plus prednisone in 950 patients with castrate-refractory prostate cancer (CRPC) who had progressed after initial chemotherapy. The data presented are retrospective analyses of the SPARC trial evaluating correlations between overall survival (OS) and pain at baseline, pain progression, and progression-free survival (PFS) at three months.
Oncology

Clinical Study Shows Value Of Nexstim's Navigated Brain Stimulation (NBS) In Eloquent Cortex Surgery

Nexstim Oy, a medical device company developing non-invasive brain diagnostics and therapy technologies, announces presentation of the abstract "TMS as a part of multimodal management of safe glioma resection in the motor cortex" at the 60th Annual Meeting of the German Society of Neurosurgery. Clinicians at the distinguished Department of Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt, Germany compared the results of non-invasive TMS, using Nexstim"s Navigated Brain Stimulation (NBS) System, and fMRI with the results of invasive direct cortical stimulation (DCS) in patients with tumors in or near the motor cortex. The clinicians noted that in all patients "TMS showed congruence with DCS. In contrast to fMRI, TMS and DCS enabled identification of eloquent cortex within the tumor." In addition, the Frankfurt clinicians concluded that "TMS (as part of Nexstim"s NBS System) may call into question categorizing tumors in the motor cortex as unresectable, since TMS anticipates information usually only enabled by invasive DCS." Abstract: click here. Jukka-Pekka Sç¤rkkç¤, Managing Director of Nexstim commented, "The Frankfurt study confirms our belief that NBS overcomes the limitations of fMRI and we were pleased with the enormous interest in NBS at this important meeting." About NBS in neurosurgery Unlike functional magnetic resonance imaging (fMRI), NBS is a direct method, like DCS, for accurate mapping of the cerebral cortex. DCS is considered the gold standard but it is an invasive technique and can require a large, awake craniotomy. Accurate presurgical maps of the vital functional areas of the cortex, enabled by NBS, allow selection of the optimal treatment strategy for the individual patient, they also save valuable time in the OR and have the potential to enable better patient outcomes. NBS System is CE-marked. Caution: in the United States the NBS System is limited by Federal law to investigational use. Nexstim

Breast Enhancement commented:

A best discussion on bypass surgery according to me. I totally agree with the information mentioned here

01.05.2012


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009